I understand your concerns, but I respectfully disagree with your assessment that there are technology limitations hindering PCK's success. The company has conducted numerous successful clinical trials and has received regulatory approvals in multiple countries. Furthermore, PCK has continued to improve and expand their product offerings, which has potential to significantly increase their market share. While the government grant may have helped with initial uptake, PCK's recent partnerships and commercial agreements demonstrate that their technology is gaining traction and interest from the healthcare industry. Therefore, I believe that any stalled uptake is likely due to external factors rather than inherent limitations with PCK's technology.
